Avidity Biosciences Inc. (NASDAQ:RNA) is one of 15 stocks with the biggest hedge fund momentum, after gaining 28 hedge fund holders during the fourth quarter of 2025. On February 23, Avidity Biosciences Inc. (NASDAQ:RNA) adjourned its special stockholder meeting scheduled for the same day and moved the date to February 26. Avidity Biosciences Inc. (NASDAQ:RNA) said it needs additional time to satisfy conditions for the distribution of all outstanding shares of Atrium Therapeutics Inc. to Avidity stockhol ...

Atrium Therapeutics Launches with Approximately $270 Million to Advance Novel RNA Medicines for Rare Genetic Cardiomyopathies [Accessibility Statement] Skip NavigationSpinoff from Novartis AG's acquisition of Avidity Biosciences advances precision cardiology programs using targeted RNA delivery platformLead candidates ATR 1072 and ATR 1086 expected to enter clinical trials for PRKAG2 syndrome and PLN cardiomyopathy, respectivelySAN DIEGO, Feb. 27, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) ...

Avidity Biosciences, Inc. (formerly NASDAQ: RNA, temporarily RNAM) is a clinical-stage biopharmaceutical company focused on developing a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™) for serious diseases, including rare genetic cardiomyopathies and neuromuscular disorders. On February 23, 2026, Avidity announced it would convene its special stockholder meeting as scheduled and immediately adjourn it without conducting business. The meeting reconvened on February 26, 2026, ...

Avidity Biosciences Announces Intention to Adjourn and Reconvene Special Meeting of Stockholders [Accessibility Statement] Skip NavigationSAN DIEGO, Feb. 23, 2026 /PRNewswire/ -- Avidity Biosciences, Inc. ("Avidity") (NASDAQ: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates ("AOCsâ"¢") to profoundly improve people's lives, today announced that it intends to convene its upcoming special meeting of stockholders (the "Special M ...

Core Viewpoint - Novartis India Limited's shares surged after a consortium led by ChrysCapital announced the acquisition of Novartis AG's 70.68% stake in the Indian subsidiary, leading to a mandatory open offer for public shareholders [1][4]. Group 1: Stock Performance - The stock was trading at ₹953.85 on BSE, reflecting an increase of ₹123.40 or 14.86% from the previous close of ₹830.45 [1]. - The share price reached the upper limit of ₹996.50 earlier in the session before slightly declining [3]. - The turnover was ₹80.72 crore with a volume of 8.24 lakh shares, significantly higher than the two-week average of 0.23 lakh shares, indicating strong investor interest [3]. Group 2: Acquisition Details - The consortium, including WaveRise Investments Limited, ChrysCapital Fund X, and Two Infinity Partners, signed a Share Purchase Agreement to acquire 1,74,50,680 equity shares for approximately ₹1,446 crore [4]. - The acquisition triggered a mandatory open offer under SEBI regulations, allowing the purchase of up to 64,19,608 shares, which represents 26% of the voting share capital, at a price of ₹860.64 per share, totaling approximately ₹552 crore if fully subscribed [6]. Group 3: Open Offer and Company Changes - The open offer price of ₹860.64 is at a discount to the current market price of ₹953.85, reflecting market expectations regarding deal certainty and potential price adjustments [7]. - The acquirers indicated that the offer price may be revised upward if any adjustments in the Share Purchase Agreement lead to a higher figure [7]. - Novartis India's board has approved a covenant and warranty deed related to the transaction, and the company is required to change its name within 120 days of deal closure [7].

Group 1 - Daiichi Sankyo has appointed John Tsai, MD as the new Global Head of R&D, effective April 1, 2026, succeeding Ken Takeshita, MD [1] - Dr. Tsai brings over 25 years of experience in driving innovation and leadership in the biotech and pharmaceutical sectors, previously serving at Syncona Investment Management and Novartis AG [1] - The company aims to leverage Dr. Tsai's expertise to enhance its R&D pipeline and accelerate the development of new medicines [1] Group 2 - Daiichi Sankyo has established a new research institute in San Diego, marking its third research facility outside Japan, following locations in Boston and Munich [1] - The company emphasizes its commitment to deepening relationships in key scientific hubs to foster innovation in healthcare [1]

Core Viewpoint - Tarsus Pharmaceuticals has appointed David E. I. Pyott, a prominent figure in the biopharmaceutical industry and former CEO of Allergan, to its Board of Directors, which is expected to enhance the company's growth and innovation in eye care and other therapeutic areas [1][2][10]. Company Overview - Tarsus Pharmaceuticals focuses on revolutionizing treatment for patients, particularly in eye care, and is advancing its pipeline to address diseases with high unmet needs across various therapeutic categories, including dermatology and infectious disease prevention [5]. Leadership Experience - David E. I. Pyott has over 17 years of experience as CEO of Allergan, where he grew the company from approximately $1 billion in sales to over $7 billion in revenue, demonstrating a strong ability to navigate market complexities while maintaining a focus on long-term growth [2][3]. - Pyott has also held significant roles at Novartis and has been recognized as one of Harvard Business Review's "100 Best Performing CEOs in the World" [2]. Strategic Vision - Pyott expressed enthusiasm about joining Tarsus at a pivotal time, highlighting the company's strong foundation with its lead product and promising pipeline, and his commitment to building long-term value and advancing innovation in eye care [3]. Current Developments - Tarsus's lead commercial product, XDEMVY (lotilaner ophthalmic solution) 0.25%, is FDA approved for treating Demodex blepharitis, and the company is also developing additional treatments, including TP-04 for ocular rosacea and TP-05 for Lyme disease prevention, both currently in Phase 2 trials [5].

Core Insights - Entera Bio Ltd. has appointed Geno J. Germano as Chairman of the Board, effective February 4, 2026, succeeding Gerald Lieberman [1] - The company is advancing two oral PTH peptide programs into clinical testing in 2026, including a Phase 3 study for EB613 in osteoporosis and a first-in-human study for Long-Acting Oral PTH in hypoparathyroidism [2] Company Developments - Entera's lead clinical asset, EB613, is positioned to transform osteoporosis treatment by providing an oral anabolic therapy, which could broaden its use among patients [3] - The company has established a foundation for its oral peptide pipeline and is transitioning to late-stage clinical testing, with Germano's leadership expected to enhance its development and commercialization efforts [3][4] Leadership Background - Geno J. Germano brings over 30 years of experience in the pharmaceutical and life sciences sectors, having held senior roles at Pfizer, including leading a $14 billion innovative medicines portfolio [4] - Germano's previous board experience includes roles at various biotechnology companies, indicating a strong background in guiding clinical-stage firms [4] Product Pipeline - Entera is focused on developing oral peptide and protein replacement therapies, leveraging its proprietary N-Tab® technology platform [5] - The company's most advanced product, EB613, is being developed as the first oral treatment for post-menopausal women with low bone mineral density and high-risk osteoporosis [5] - Additional programs include an oral PTH(1-34) tablet for hypoparathyroidism and an oral oxyntomodulin for obesity and metabolic syndromes [5]

Core Viewpoint - Cognizant Technology Solutions Corp. achieved a 6.95% dollar revenue growth in 2025, reaching $21.12 billion, marking its best performance since 2021 and a significant recovery from a revenue decline in 2023 [1] Revenue Growth - Cognizant's growth was primarily driven by product and resource sales, contributing over a third of its revenue growth, which is higher than HCL Technologies' 5.1% growth [2] - The company outperformed major Indian IT firms, with Infosys reporting $19.85 billion (3.85% growth), Tata Consultancy Services at $29.86 billion (down 0.72%), and Wipro at $10.42 billion (down 1.41%) [3] Major Contracts - The company signed three contracts exceeding $1 billion in 2025, including a significant $1 billion IT modernization deal with Novartis AG [4] Future Outlook - Cognizant anticipates revenue between $22.14 billion and $22.66 billion for 2026, indicating a growth rate of 4.9-7.4%, with 1.5% expected from acquisitions [7] - The company is considering a share listing in India to enhance valuations, although specific details remain undisclosed [8] Profitability - Profitability improved, with a 140 basis point increase to 16.1%, although net profit slightly decreased by 0.45% to $2.23 billion [10] Employee Growth - The company increased its workforce to 351,600 employees, gaining 14,800 from the previous year, contrasting with TCS's reduction of nearly 20,000 employees [11] Market Reaction - Following the positive results, Cognizant's shares rose by 2.71% to $76.52 in pre-market trading, indicating strong shareholder confidence [12] Execution and Strategy - The growth is attributed to improved execution and deal conversion rather than a sudden demand rebound, with a focus on large client mining and cost discipline [13]

Core Viewpoint - Avidity Biosciences is set to distribute shares of Atrium Therapeutics to its stockholders as part of a merger with Novartis AG and a spin-off of its early-stage precision cardiology programs [1][2] Company Overview - Avidity Biosciences focuses on RNA therapeutics, specifically Antibody Oligonucleotide Conjugates (AOCs), aiming to improve treatment for diseases previously unreachable with existing RNA therapies [3] - The company has developed a proprietary AOC platform that successfully targets RNA delivery into muscle, with ongoing clinical programs for myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral muscular dystrophy [3] - Avidity is also advancing two precision cardiology candidates targeting rare genetic cardiomyopathies and expanding its pipeline through partnerships in cardiology and immunology [3] Transaction Details - The record date for the distribution of SpinCo shares is set for February 12, 2026, with stockholders receiving one share of SpinCo for every ten shares of Avidity held [1] - The completion of the merger and spin-off is contingent upon certain closing conditions, including stockholder approval, which may affect the record date [2]